Peptide Monograph

Melanotan II

Synthetic Cyclic Heptapeptide — Alpha-MSH Analog

At a Glance

Mechanism of Action

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was originally developed at the University of Arizona by researchers seeking a photoprotective tanning agent. Unlike the linear, rapidly degraded native alpha-MSH, MT-II's cyclic structure confers significantly greater metabolic stability and receptor binding potency.[1]

MT-II is a non-selective melanocortin receptor agonist, meaning it activates multiple melanocortin receptor subtypes (MC1R through MC5R) with varying affinities. This broad receptor activity profile underlies both its desired effects and its significant side effect burden:[2]

• MC1R activation — Stimulates melanogenesis in epidermal melanocytes, promoting the synthesis and dispersion of melanin (eumelanin). This produces skin darkening (tanning) without requiring ultraviolet radiation exposure, though UV exposure accelerates and deepens the effect.[1]
• MC3R / MC4R activation — These centrally expressed receptors mediate the sexual arousal and erectile responses observed with MT-II. The discovery that MT-II caused penile erections as a side effect in early clinical trials led directly to the development of bremelanotide (PT-141), a more selective MC3R/MC4R agonist now FDA-approved for hypoactive sexual desire disorder.[3]
• MC4R activation — Also drives appetite suppression and reduced food intake through hypothalamic pathways, contributing to the weight loss and decreased hunger commonly reported by users.[4]
• MC3R activation — Involved in energy homeostasis and fat metabolism regulation.[4]
• MC5R activation — Plays a role in exocrine gland function, though the clinical significance of MT-II's activity at this receptor is not well characterized.

The non-selective nature of MT-II is both its defining pharmacological feature and its primary clinical liability. While MC1R activation produces the desired tanning effect, simultaneous activation of MC3R-MC5R produces a wide range of additional physiological effects that cannot be separated from the tanning action at any dose.[2]

Evidence Summary

Clinical Studies

Dorr et al. conducted the initial Phase I clinical studies of Melanotan II in human subjects at the University of Arizona. Subcutaneous administration produced significant skin darkening, measured by reflectance spectrophotometry, without UV exposure. The melanogenic effect was dose-dependent and reversible upon cessation.[1]

Hadley and Dorr reported that subjects in Phase I studies experienced penile erections as an unexpected side effect, occurring in the majority of male participants. This serendipitous finding redirected research efforts toward developing melanocortin-based treatments for sexual dysfunction, ultimately producing bremelanotide (PT-141).[3]

Additional small studies examined MT-II's effects on sexual arousal in both men and women, confirming centrally mediated pro-erectile and pro-sexual effects. However, the non-selective receptor profile and associated side effects (particularly nausea) precluded further clinical development of MT-II itself.[2]

Safety Concerns from Recreational Use

Brennan and Kling conducted a systematic analysis of Melanotan II use in the community and documented a pattern of adverse events including nausea, facial flushing, injection site reactions, and darkening of pre-existing moles and nevi. Critically, they highlighted the potential concern that pharmacological stimulation of melanocytes could theoretically promote melanocytic neoplasia in predisposed individuals.[5]

Langan et al. reported cases of changed moles, new nevi, and atypical melanocytic lesions in individuals using Melanotan II, raising serious concerns about the potential relationship between MT-II use and melanoma development. While a direct causal relationship has not been established, these reports underscore the importance of dermatologic surveillance in any individual who has used this peptide.[6]

Primary Uses (Recreational / Investigational)

Melanotan II has been investigated or used recreationally for the following purposes:

• Sunless tanning — The primary recreational use. MC1R-mediated melanogenesis produces progressive skin darkening. UV exposure is not required but accelerates and deepens tanning. This was the original intended therapeutic application.[1]
• Photoprotection — The original research rationale was that increased eumelanin would provide protection against UV-induced DNA damage and reduce skin cancer risk. Ironically, concerns about melanocyte stimulation and melanoma risk now dominate the safety discussion.[1]
• Sexual dysfunction — MC3R/MC4R-mediated pro-erectile and pro-sexual effects. This application led to the development of bremelanotide (PT-141), which received FDA approval for hypoactive sexual desire disorder in premenopausal women in 2019.[3]
• Appetite suppression / fat loss — MC4R-mediated reduction in food intake and appetite. Users commonly report reduced hunger during MT-II use.[4]

Contraindications

Standard Protocols

Harm reduction note: Many experienced users recommend starting with very low doses (0.1 mg) and titrating upward slowly to minimize the often-severe nausea that accompanies initial dosing. Administering before bedtime can reduce the subjective experience of nausea and facial flushing. Antihistamines (e.g., cetirizine) are sometimes used to mitigate flushing.

Common Stacks & Synergies

Melanotan II is sometimes combined with other compounds in the recreational and self-experimentation community. The following combinations are commonly discussed but have no published clinical evidence supporting their safety or efficacy:

• MT-II + UV exposure — The most common combination. Low to moderate UV exposure (sun or tanning bed) after MT-II administration accelerates melanogenesis. This combination carries compounded skin cancer risk from both UV exposure and melanocyte stimulation.
• MT-II + PT-141 (bremelanotide) — Some users combine both peptides, though this is pharmacologically redundant since PT-141 is itself a metabolite derivative of MT-II with a more selective receptor profile. Concurrent use would likely increase side effects without clear benefit.
• MT-II + antihistamines/anti-nausea agents — Cetirizine, ondansetron, or ginger are commonly co-administered to manage the nausea and flushing that frequently accompany MT-II dosing.

Preparation & Administration

Melanotan II is supplied as a lyophilized (freeze-dried) powder, typically in 10 mg vials. It must be reconstituted with bacteriostatic water (BAC water) before injection.

Reconstitution

For a standard 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 0.5 mg. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Common injection sites include the abdominal subcutaneous tissue. Rotate injection sites to avoid lipodystrophy. Many users inject before bedtime to minimize the subjective impact of nausea and flushing. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Side Effects & Adverse Events

Common side effects (reported in clinical studies and community use):

• Nausea — Very common, especially at initial doses and higher doses. Often described as the most limiting side effect. Typically diminishes with repeated dosing (tachyphylaxis) but may persist in some individuals.[5]
• Facial flushing — Common, occurring within minutes of injection. Usually resolves within 1–2 hours.[1]
• Spontaneous erections — Common in males. This effect was observed in Phase I trials and led to the development of bremelanotide for sexual dysfunction.[3]
• Fatigue and drowsiness — Commonly reported, particularly in the hours following injection.
• Appetite suppression — MC4R-mediated reduction in hunger. May be significant and sustained during loading phases.[4]
• Darkening of existing moles and nevi — An important safety concern. New moles may also appear. Any changes in moles should prompt immediate dermatologic evaluation to rule out melanoma.[6]
• Injection site reactions — Redness, swelling, or mild pain at the injection site.
• Yawning and stretching — An unusual but commonly reported effect, likely mediated by central melanocortin signaling.

Serious concerns:

• Melanoma risk modification — The most significant long-term safety concern. Direct stimulation of melanocytes raises the theoretical possibility of promoting melanocytic neoplasia. Case reports exist but a causal relationship has not been established.[6]
• Blood pressure changes — Both hypertensive and hypotensive episodes have been reported.
• Unregulated product quality — As MT-II is sold exclusively through unregulated channels, contamination, incorrect dosing, and degraded products are significant risks.[5]

Drug Interactions

No formal drug interaction studies have been conducted with Melanotan II in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Antihypertensives — MT-II can affect blood pressure. Concurrent use with antihypertensive medications may result in unpredictable blood pressure responses, including hypotension.
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) — Combined use with MT-II's pro-erectile effects may result in prolonged or painful erections (priapism). This combination should be avoided.[3]
• Immunosuppressants — Melanocortin receptors have immunomodulatory functions. Theoretical interactions with immunosuppressive therapy are possible but not characterized.
• Other melanocortin agonists (PT-141, afamelanotide) — Concurrent use would produce additive melanocortin receptor activation and is pharmacologically redundant with increased side effect risk.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption." The FDA has issued warnings about unlicensed tanning injections including Melanotan II.
• WADA (World Anti-Doping Agency) — Melanotan II is prohibited at all times under the WADA Prohibited List (Section S0: Non-Approved Substances and S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics).
• Australia (TGA) — Banned. The Therapeutic Goods Administration has explicitly warned consumers against using Melanotan products and seized shipments. Classified as a prescription-only substance.
• European Union — Not approved as a medicinal product. Multiple EU member states have issued specific warnings against Melanotan II. Regulatory action varies by country.
• United Kingdom (MHRA) — The Medicines and Healthcare products Regulatory Agency has issued public warnings against Melanotan products, classifying them as unlicensed medicines.

Open Questions

Significant unresolved questions surround Melanotan II, particularly regarding long-term safety:

• Melanoma risk — The central unresolved question. Does pharmacological stimulation of melanocytes promote melanoma development, provide photoprotection through increased eumelanin, or have a neutral effect? Epidemiological data is lacking and confounded by concurrent UV exposure in most users.[6]
• Long-term safety of chronic use — Many recreational users employ MT-II cyclically for years. No long-term safety data exists for this pattern of use. The consequences of repeated melanocyte stimulation over years or decades are unknown.
• Product quality and contamination — All commercially available MT-II comes from unregulated sources. The true peptide content, purity, sterility, and potential for contamination with harmful substances are unknown for any given product.[5]
• Interaction with UV-induced carcinogenesis — Most MT-II users combine the peptide with UV exposure (sun or tanning beds). Whether MT-II modifies UV-induced DNA damage, repair mechanisms, or carcinogenesis pathways is not established.
• Dose-response relationship in humans — Optimal dosing for efficacy and safety has never been rigorously determined in controlled human studies.
• Reversibility of effects — While tanning generally fades after cessation, the reversibility of mole changes and other melanocytic effects is not well characterized.

Bibliography

1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sci. 1996;58(20):1777-84. doi:10.1016/0024-3205(96)00160-9. PMID:8637402.
2. Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-30. doi:10.1016/j.peptides.2005.01.029. PMID:16412534.
3. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr RT, Levine N. "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study." J Urol. 1998;160(2):389-93. doi:10.1016/S0022-5347(01)62906-6. PMID:9679884.
4. Hruby VJ, Cai M, Grieco P, Han G, Kavarana M, Trivedi D. "Exploring the stereostructural requirements of peptide ligands for the melanocortin receptors." Ann N Y Acad Sci. 2003;994:12-20. doi:10.1111/j.1749-6632.2003.tb03157.x. PMID:12851292.
5. Brennan R, Wells JG, Van Hout MC. "The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review." Health Soc Care Community. 2017;25(5):1459-1531. doi:10.1111/hsc.12326. PMID:26806443.
6. Langan EA, Nie Z, Rhodes LE. "Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?" Br J Dermatol. 2010;163(3):451-5. doi:10.1111/j.1365-2133.2010.09891.x. PMID:20545686.